Accéder au contenu
Merck

UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.

Cell stem cell (2021-01-09)
Jalila Chagraoui, Simon Girard, Jean-Francois Spinella, Laura Simon, Eric Bonneil, Nadine Mayotte, Tara MacRae, Jasmin Coulombe-Huntington, Thierry Bertomeu, Celine Moison, Elisa Tomellini, Pierre Thibault, Mike Tyers, Anne Marinier, Guy Sauvageau
RÉSUMÉ

Human hematopoietic stem cells (HSCs) exhibit attrition of their self-renewal capacity when cultured ex vivo, a process that is partially reversed upon treatment with epigenetic modifiers, most notably inhibitors of histone deacetylases (HDACs) or lysine-specific demethylase LSD1. A recent study showed that the human HSC self-renewal agonist UM171 modulates the CoREST complex, leading to LSD1 degradation, whose inhibition mimics the activity of UM171. The mechanism underlying the UM171-mediated loss of CoREST function remains undetermined. We now report that UM171 potentiates the activity of a CULLIN3-E3 ubiquitin ligase (CRL3) complex whose target specificity is dictated by the poorly characterized Kelch/BTB domain protein KBTBD4. CRL3KBTBD4 targets components of the LSD1/RCOR1 corepressor complex for proteasomal degradation, hence re-establishing H3K4me2 and H3K27ac epigenetic marks, which are rapidly decreased upon ex vivo culture of human HSCs.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Valproic acid sodium salt, 98%
Sigma-Aldrich
Anticorps anti-histone H3, 0.5 mg/mL, Upstate®
Sigma-Aldrich
M344, ≥98% (HPLC), powder
Sigma-Aldrich
LMK235, ≥98% (HPLC)